Director Group Finance emphasised recent milestones.
Several growth drivers from product innovation and portfolio expansion Quarterly volatility is part ...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) har nyligen rapporterat årets f...
CirChem (”CirChem” eller ”Bolaget”) har publicerat Bolagets delårsrapport för det första kvartalet 2...
Q1 confirms that Terclara defends a leading market position in Sweden and that the Norwegian launch ...
Redeye provides an update on Acarix following its Q1 report, which showed continued growth in revenu...
Q1 was an active quarter for Cantargia. Among other things, positive multiple ascending dose results...
Med en framgångsrik företrädesemission i ryggen, som tillförde AcuCort AB (”AcuCort” eller ”Bolaget”...
Irisity AB (”Irisity” or ”the Company”) published its Q1 report for 2025 on the 13th of May 2025.
Q1 sales 20% below cons, partly driven by Brazil impact Adj.
Redeye provides an initial take following the release of SenzaGen’s Q1 2025 report.
Redeye comments on Gentoo Media’s Q1-results which were lower than expected owing to a larger than a...
Redeye updates on Better Collective ahead of Q4-results (due 21 May after market close) where focus ...
Redeye provides its initial take on Surgical Science’s Q1 2025 report, which mostly beat our estimat...
Redeye updates its estimates and fair value range following CoinShares' Q1 2025 report.
Redeye returns with an updated view following Nekkar’s Q1 figures that was surprisingly soft even if...
Relais' Q1 results were well in line with LSEG Data and Analytics consensus expectations, while the ...
Strong momentum in GC&MP, headwinds in NW&FT and FW '25e-'27e sales CAGR of +14% New product launche...
Expect continued M&A, mainly in DACH 5% adj. EBITA CAGR '24-'27e, M&A to support 10% growth 10-7x EB...
CEO Daniel Krook emphasised the increased growth focus for H1.
